Brought to you by 
Alnylam partners ALNRSV01 with Kyowa in Asia
Jun 2008
Executive Summary
In its second tie-up with a Japanese pharmaco in less than a month, RNA interference specialist Alnylam Pharmaceuticals has granted Kyowa Hakko Kogyo exclusive rights to develop and market its lead therapeutic ALNRSV01 for respiratory syncytial virus (RSV) in Japan and other Asian countries.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com